Research and Markets: World Benign Prostatic Hyperplasia Therapeutics Pipeline Review 2015 - 25 Companies & 36 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/4tqgdx/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Addex Therapeutics Ltd
  • AmVac AG
  • AndroScience Corporation
  • Aphios Corporation
  • Ausio Pharmaceuticals, LLC
  • BCWorld Pharm Co. Ltd.
  • Biolab Sanus Farmaceutica Ltda.
  • Chong Kun Dang Pharmaceutical Corp.
  • Dongkook Pharmaceutical Co., Ltd.
  • Euroscreen S.A.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • IntelGenx Corp.
  • Jeil Pharmaceutical Co., Ltd.
  • KAEL-GemVax Co., Ltd.
  • Kaken Pharmaceutical Co., Ltd.
  • Meiji Seika Pharma Co., Ltd.
  • Mezzion Pharma Co. Ltd.
  • Monosol Rx, LLC
  • Nymox Pharmaceutical Corporation
  • Ono Pharmaceutical Co., Ltd.
  • Quest PharmaTech Inc.
  • SK Chemicals Co., Ltd.
  • SOM Innovation Biotech SL
  • Sophiris Bio, Inc.
  • Yungjin Pharm. Co., Ltd.

Drug Profiles

  • (dutasteride + tadalafil)
  • (solifenacin succinate + tamsulosin hydrochloride)
  • (tamsulosin hydrochloride + dutasteride)
  • ADX-68692
  • AMV-110
  • ASC-JM.X2
  • AUS-131
  • BCWPE-004
  • BL-214
  • CKD-902
  • ESN-364
  • fexapotide triflutate
  • HCP-1303
  • HIP-1402
  • INT-0031
  • L-1AD3
  • MCS-2
  • Micselon
  • NCE-403
  • ONO-8430506
  • S-40542
  • SL-052
  • Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia
  • SOM-2391
  • SOM-2393
  • Sperol
  • Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology
  • tadalafil
  • talaporfin sodium
  • tamsulosin hydrochloride CR
  • tamsulosin hydrochloride DR
  • tertomotide
  • topsalysin
  • udenafil
  • YBH-1603

For more information visit http://www.researchandmarkets.com/research/4tqgdx/benign_prostatic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals